Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma (vol 15, pg 737, 2015)

被引：3
|
作者：
Richardson, P. G. [1 ]
Laubach, J. P. [1 ]
Lonial, S. [1 ]
机构：
[1] Univ Navarra Clin, IDISNA, CIMA, Pamplona, Spain
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 09期
关键词：
D O I：
10.1586/14737140.2015.1071726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1121 / 1121
页数：1
相关论文
共 50 条
  • [1] Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma
    Richardson, Paul G.
    Laubach, Jacob P.
    Lonial, Sagar
    Moreau, Philippe
    Yoon, Sung-Soo
    Hungria, Vania T. M.
    Dimopoulos, Meletios A.
    Beksac, Meral
    Alsina, Melissa
    San-Miguel, Jesus F.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (07) : 737 - 748
  • [2] Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
    Wolf, Jeffrey L.
    Siegel, David
    Goldschmidt, Hartmut
    Hazell, Katharine
    Bourquelot, Priscille M.
    Bengoudifa, Bourras R.
    Matous, Jeffrey
    Vij, Ravi
    de Magalhaes-Silverman, Margarida
    Abonour, Rafat
    Anderson, Kenneth C.
    Lonial, Sagar
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1820 - 1823
  • [3] Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma
    Wahaib, Kristy
    Beggs, Ashton E.
    Campbell, Hope
    Kodali, Leela
    Ford, Patrick D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (07) : 441 - 450
  • [4] Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
    Richardson, Paul G.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael
    Mukhopadhyay, Sutapa
    Snodgrass, Susan
    Schlossman, Robert
    BLOOD, 2011, 118 (21) : 370 - 371
  • [5] Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
    Redic, Kimberly A.
    Hough, Shannon M.
    Price, Erika M.
    ONCOTARGETS AND THERAPY, 2016, 9 : 2783 - 2793
  • [6] Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
    Richardson, Paul G.
    Harvey, R. Donald
    Laubach, Jacob P.
    Moreau, Philippe
    Lonial, Sagar
    San-Miguel, Jesus F.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (01) : 35 - 48
  • [7] Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
    Greig, Sarah L.
    TARGETED ONCOLOGY, 2016, 11 (01) : 107 - 114
  • [8] Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma
    Sarah L. Greig
    Targeted Oncology, 2016, 11 : 107 - 114
  • [9] Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
    Afifi, Salma
    Michael, Angela
    Azimi, Mahshid
    Rodriguez, Mabel
    Lendvai, Nikoletta
    Landgren, Ola
    PHARMACOTHERAPY, 2015, 35 (12): : 1173 - 1188
  • [10] The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma
    Andreu-Vieyra, Claudia V.
    Berenson, James R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2014, 5 (06) : 197 - 210
12345